![](/images/graphics-bg.png)
Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
Joint Authors
Gackowska, Lidia
Banach, J.
Wołowiec, Ł.
Rogowicz, D.
Gilewski, W.
Sinkiewicz, W.
Michalkiewicz, Jacek
Kubiszewska, Izabela
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-08-28
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Introduction.
Procalcitonin (PCT) is an excellent marker of sepsis but was not extensively studied in cardiology.
The present study investigated PCT plasma concentration in patients with chronic heart failure with reduced ejection fraction (HFrEF) and its prognostic value during 24-month follow-up.
Material and Methods.
Study group consisted of 130 patients with HFrEF (LVEF ≤ 45%) and 32 controls.
PCT level was assessed on admission in all patients.
Telephone follow-up was performed every three months over a period of 2 years.
Endpoints were death of all causes and readmission for HFrEF exacerbation.
Results.
HFrEF patients had significantly higher PCT concentration than controls (166.95 versus 22.15 pg/ml; p<0.001).
Individuals with peripheral oedema had increased PCT comparing to those without oedema (217.07 versus 152.12 pg/ml; p<0.02).
In ROC analysis, PCT turned out to be a valuable diagnostic marker of HFrEF (AUC 0.91; p<0.001).
Kaplan-Meier survival curves revealed that patients with PCT in the 4th quartile had significantly lower probability of survival than those with PCT in the 1st and 2nd quartiles.
In univariate, but not multivariate, analysis, procalcitonin turned out to be a significant predictor of death during 24-month follow-up.
(HR 1.002; 95% CI 1.000–1.003; p<0.03).
Conclusions.
Elevated PCT concentration may serve as another predictor of worse outcome in patients with HFrEF.
American Psychological Association (APA)
Banach, J.& Wołowiec, Ł.& Rogowicz, D.& Gackowska, Lidia& Kubiszewska, Izabela& Gilewski, W.…[et al.]. 2018. Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF). Disease Markers،Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1153782
Modern Language Association (MLA)
Banach, J.…[et al.]. Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF). Disease Markers No. 2018 (2018), pp.1-6.
https://search.emarefa.net/detail/BIM-1153782
American Medical Association (AMA)
Banach, J.& Wołowiec, Ł.& Rogowicz, D.& Gackowska, Lidia& Kubiszewska, Izabela& Gilewski, W.…[et al.]. Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF). Disease Markers. 2018. Vol. 2018, no. 2018, pp.1-6.
https://search.emarefa.net/detail/BIM-1153782
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1153782